# US 2016/0251353 A1 · Inhibitors of influenza viruses replication

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251353 A1
- Document ID: US20160251353A1
- Status: Published application
- Kind: A1
- Application number: 15/150,459
- Filed: 2016-05-10
- Published: 2016-09-01
- Earliest claimed: 2013-11-13
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Kwame W. Nti-Addae; Michael Waldo; Simon Adam O'Neil; John Gregg Van Alsten; Dainius Macikenas; Praveen Mudunuri; Yi Shi; Mark Willem Ledeboer; Valdas Jurkauskas; Ales Medek; Steven Jones; Randal Byrn; Mohammed Asmal; Sarah Marie Robertson; Wanjung Tsai
- Web page: https://patentgrep.com/patent/US20160251353A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/351: not condensed with another ring
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 309/30: of six-membered aromatic rings substituted by alkyl groups
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.

## Claims

### Claim 1

A polymorphic form of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula:
and wherein the polymorphic form is selected from the group consisting of:
Form A of HCl salt of Compound (1).½H2O,
Form F of HCl salt of Compound (1).3H2O,
Form D of HCl salt of Compound (1),
Form A of Compound (1), and
Form A of tosylate salt of Compound (1).

### Claim 2 (depends on 1)

The polymorphic form of claim 1, wherein the polymorphic form is Form A of HCl salt of Compound (1).½H2O.

### Claim 3 (depends on 2)

The polymorphic form of claim 2, wherein Form A of HCl salt of Compound (1).½H2O is characterized by one or more peaks corresponding to 2-theta values measured in degrees of 10.5±0.2, 5.2±0.2, 7.4±0.2, and 18.9±0.2 in an X-ray powder diffraction pattern.

### Claim 4 (depends on 3)

The polymorphic form of claim 3, wherein Form A of HCl salt of Compound (1).½H2O is further characterized by one or more peaks corresponding to 2-theta values measured in degrees of 25.2±0.2, 16.5±0.2, 18.1±0.2, and 23.0±0.2 in an X-ray powder diffraction pattern.

### Claim 5 (depends on 2, 3, 4)

The polymorphic form of any of claims 2-4, wherein Form A of HCl salt of Compound (1).½H2O is characterized by one or more peaks corresponding to 29.2±0.3 ppm, 107.0±0.3 ppm, 114.0±0.3 ppm, and 150.7±0.3 ppm in a C13 SSNMR spectrum.

### Claim 6 (depends on 5)

The polymorphic form of claim 5, wherein Form A of HCl salt of Compound (1).½H2O is further characterized by one or more peaks corresponding to 22.1±0.3 ppm, 24.6±0.3 ppm, 47.7±0.3 ppm, and 54.8±0.3 ppm in a C13 SSNMR spectrum.

### Claim 7 (depends on 1)

The polymorphic form of claim 1, wherein the polymorphic form is Form F of HCl salt of Compound (1).3H2O.

### Claim 8 (depends on 7)

The polymorphic form of claim 7, wherein Form F of HCl salt of Compound (1).3H2O is characterized by one or more peaks corresponding to 2-theta values measured in degrees of 7.1±0.2, 11.9±0.2, 19.2±0.2, and 12.4±0.2 in an X-ray powder diffraction pattern.

### Claim 9 (depends on 8)

The polymorphic form of claim 8, wherein Form F of HCl salt of Compound (1).3H2O is further characterized by one or more peaks corresponding to 2-theta values measured in degrees of 16.4±0.2, 21.8±0.2, and 23.9±0.2 in an X-ray powder diffraction pattern.

### Claim 10 (depends on 7, 8, 9)

The polymorphic form of any of claims 7-9, wherein Form F of HCl salt of Compound (1).3H2O is characterized by one or more peaks corresponding to 20.7±0.3 ppm, 27.4±0.3 ppm, 104.8±0.3 ppm, 142.5±0.3 ppm, and 178.6±0.3 ppm in a C13 SSNMR spectrum.

### Claim 11 (depends on 10)

The polymorphic form of claim 10, wherein Form F of HCl salt of Compound (1).3H2O is further characterized by one or more peaks corresponding to 154.3±0.3 ppm, 20.3±0.3 ppm, 132.3±0.3 ppm, and 21.1±0.3 ppm in a Cu SSNMR spectrum.

### Claim 12 (depends on 1)

The polymorphic form of claim 1, wherein the polymorphic form is Form D of HCl salt of Compound (1).

### Claim 13 (depends on 12)

The polymorphic form of claim 12, wherein Form D of HCl salt of Compound (1) is characterized by one or more peaks corresponding to 2-theta values measured in degrees of 5.8±0.2, 19.5±0.2, and 17.1±0.2 in an X-ray powder diffraction pattern.

### Claim 14 (depends on 13)

The polymorphic form of claim 13, wherein Form D of HCl salt of Compound (1) is further characterized by one or more peaks corresponding to 2-theta values measured in degrees of 5.3±0.2, 10.5±0.2, and 15.9±0.2 in an X-ray powder diffraction pattern.

### Claim 15 (depends on 12, 13, 14)

The polymorphic form of any of claims 12-14, wherein Form D of HCl salt of Compound (1) is characterized by one or more peaks corresponding to 29.4±0.3 ppm, 53.4±0.3 ppm, 113.3±0.3 ppm, 135.4±0.3 ppm, and 177.8±0.3 ppm in a C13 SSNMR spectrum.

### Claim 16 (depends on 15)

The polymorphic form of claim 15, wherein Form D of HCl salt of Compound (1) is further characterized by one or more peaks corresponding to 22.9±0.3 ppm, 23.9±0.3 ppm, 26.0±0.3 ppm, and 31.6±0.3 ppm in a C13 SSNMR spectrum.

### Claim 17 (depends on 1)

The polymorphic form of claim 1, wherein the polymorphic form is Form A of Compound (1).

### Claim 18 (depends on 17)

The polymorphic form of claim 17, wherein Form A of Compound (1) is characterized by one or more peaks corresponding to 2-theta values measured in degrees of 15.5±0.2, 18.9±0.2, and 22.0±0.2 in an X-ray powder diffraction pattern.

### Claim 19 (depends on 18)

The polymorphic form of claim 18, wherein Form A of Compound (1) is further characterized by one or more peaks corresponding to 2-theta values measured in degrees of 11.8±0.2, 16.9±0.2, 25.5±0.2, and 9.1±0.2 in an X-ray powder diffraction pattern.

### Claim 20 (depends on 17, 18, 19)

The polymorphic form of any of claims 17-19, wherein Form A of Compound (1) is characterized by one or more peaks corresponding to 21.0±0.3 ppm, 28.5±0.3 ppm, 50.4±0.3 ppm, 120.8±0.3 ppm, 138.5±0.3 ppm, and 176.2±0.3 ppm in a C13 SSNMR spectrum.

### Claim 21 (depends on 20)

The polymorphic form of claim 20, wherein Form A of Compound (1) is further characterized by one or more peaks corresponding to 30.1±0.3 ppm, 25.9±0.3 ppm, 22.8±0.3 ppm, and 25.0±0.3 ppm in a C13 SSNMR spectrum.

### Claim 22 (depends on 1)

The polymorphic form of claim 1, wherein the polymorphic form is Form A of tosylate salt of Compound (1).

### Claim 23 (depends on 22)

The polymorphic form of claim 22, wherein Form A of tosylate salt of Compound (1) is characterized by one or more peaks corresponding to 2-theta values measured in degrees of 7.2±0.2, 9.3±0.2, 13.7±0.2, 14.3±0.2, 14.7±0.2, 16.9±0.2, 18.7±0.2, 26.3±0.2, and 26.9±0.2 in an X-ray powder diffraction pattern.

### Claim 24 (depends on 23)

The polymorphic form of claim 23, wherein Form A of tosylate salt of Compound (1) is further characterized by one or more peaks corresponding to 2-theta values measured in degrees of 6.0±0.2, 28.0±0.2, and 27.5±0.2 in an X-ray powder diffraction pattern.

### Claim 25 (depends on 1)

A pharmaceutical composition comprising a polymorphic form according to claim 1 and at least one pharmaceutically acceptable carrier or excipient.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the polymorphic form is Form A of HCl salt of Compound (1).½H2O.

### Claim 27 (depends on 25)

The pharmaceutical composition of claim 25, wherein the polymorphic form is Form F of HCl salt of Compound (1).3H2O.

### Claim 28 (depends on 25)

The pharmaceutical composition of claim 25, wherein the polymorphic form is Form D of HCl salt of Compound (1).

### Claim 29 (depends on 25)

The pharmaceutical composition of claim 25, wherein the polymorphic form is Form A of Compound (1).

### Claim 30 (depends on 25)

The pharmaceutical composition of claim 25, wherein the polymorphic form is Form A of tosylate salt of Compound (1).

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of reducing the amount of influenza viruses in a biological in vitro sample or in a subject, comprising administering to the sample an effective amount of a polymorphic form of Compound (1) according to any one of claims 1-24.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of inhibiting the replication of influenza viruses in a biological in vitro sample or in a subject, comprising administering to the sample an effective amount of a polymorphic form of Compound (1) according to any one of claims 1-24.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of treating influenza in a subject, comprising administering to the subject a therapeutically effective amount of a polymorph form of Compound (1) according to any one of claims 1-24.

### Claim 34 (depends on 31, 32, 33)

The method of any one of claims 31-33, further comprising co-administering one or more additional therapeutic agents to the subject.

### Claim 35 (depends on 34)

The method of claim 34, wherein the additional therapeutic agents include an anti-virus drug.

### Claim 36 (depends on 35)

The method of claim 35, wherein the anti-virus drug is a neuraminidase inhibitor.

### Claim 37 (depends on 36)

The method of claim 36, wherein the neuraminidase inhibitor is oseltamivir or zanamivir.

### Claim 38 (depends on 35)

The method of claim 35, wherein the anti-virus drug is a polymerase inhibitor.

### Claim 39 (depends on 38)

The method of claim 38, wherein the polymerase inhibitor is flavipiravir.

### Claim 40 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 31-39, wherein the influenza viruses are influenza A viruses.

### Claim 41

A method of preparing Form A of HCl salt of Compound (1).½H2O, wherein Compound (1) is represented by the following structural formula:
comprising:
mixing HCl with Compound (1) in a solvent system comprising water and one or more organic solvents, wherein the solvent system has a water activity of 0.05-0.85.

### Claim 42 (depends on 41)

The method of claim 41, wherein the solvent system comprises one or more organic solvents selected from chlorobenzene, cyclohexane, 1,2-dichloroethene, dichloromethane, 1,2-dimethoxyethane, N,N-dimentylacetamide, N,N-dimethylformamide, 1,4-dioxane, 2-ethoxyethanol, formamide, hexane, 2-methoxyethanol, methylbutyl ketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, pyridine, sulfolane, tetrahydrofuran (THF), tetralin, tolune, 1,1,2-trichloroethene and xylene, acetic acid, acetone, anisole, 1-butanol, 2-butanol, butyl acetate, tert-butylmethyl ether, cumene, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, methylisobutyl ketone, 2-methyl-1-propanol, ethyl acetate, ethyl ether, ethyl formate, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, or any combination thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein the solvent system comprises one or more organic solvents selected from chlorobenzene, cyclohexane, 1,2-dichloroethane, dichloromethane, 1,2-dimethoxyethane, formamide, hexane, 2-methoxyethanol, methylbutyl ketone, methylcyclohexane, nitromethane, tetralin, xylene, toluene, 1,1,2-trichloroethane, acetone, anisole, 1-butanol, 2-butanol, butyl acetate, tert-butylmethyl ether, cumene, ethanol, ethyl acetate, ethyl ether, ethyl formate, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, 2-methy-1-propanol, pentane, 1-propanol, 1-pentanol, 2-propanol, propyl acetate, tetrahydrofuran, methyl tetrahydrofuran, or any combination thereof.

### Claim 44 (depends on 42)

The method of claim 42, wherein solvent system comprises one or more organic solvents selected from 2-ethoxyethanol, ethyleneglycol, methanol, 2-methoxyethanol, 1-butanol, 2-butanol, 3-methyl-1-butanol, 2-methyl-1-propanol, ethanol, 1-pentanol, 1-propanol, 2-propanol, methylbutyl ketone, acetone, methylethyl ketone, methylisobutyl ketone, butyl acetate, isobutyl acetate, isopropyl acetate, methyl acetate, ethyl acetate, propyl acetate, pyridine, toluene, xylene, or any combination thereof.

### Claim 45 (depends on 42)

The method of claim 42, wherein solvent system comprises one or more organic solvents selected from acetone, n-propanol, isopropanol, iso-butylacetate, acetic acid, or any combination thereof.

### Claim 46 (depends on 42)

The method of claim 42, wherein the solvent system comprises one or more organic solvents selected from acetone or isopropanol.

### Claim 47 (depends on 41, 42, 43, 44, 45, 46)

The method of any one of claims 41-46, wherein the solvent system has a water activity value of from 0.4 to 0.6.

### Claim 48 (depends on 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 41-47, wherein the mixing is performed at a temperature in a range from 5° C. to 75° C.

### Claim 49 (depends on 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 41-48, wherein the HCl is introduced as an aqueous solution having 30 wt % to 40 wt % HCl by weight of the aqueous solution.

### Claim 50

A method of preparing Form F of HCl salt of Compound (1).3H2O, wherein Compound 1 is represented by the following structural formula:
comprising:
(a) mixing HCl and Compound (1) in a solvent system comprising water, wherein the solvent system has a water activity of equal to, or greater than, 0.9; or
(b) stirring Form A of HCl salt of Compound (1).½H2O in a solvent system that comprises water, wherein the solvent system has a water activity of equal to, or greater than, 0.9.

### Claim 51 (depends on 50)

The method of claim 50, wherein the solvent system further comprises one or more organic solvents selected from chlorobenzene, cyclohexane, 1,2-dichloroethene, dichloromethane, 1,2-dimethoxyethane, N,N-dimentylacetamide, N,N-dimethylformamide, 1,4-dioxane, 2-ethoxyethanol, formamide, hexane, 2-methoxyethanol, methylbutyl ketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, pyridine, sulfolane, tetrahydrofuran (THF), tetralin, tolune, 1,1,2-trichloroethene and xylene, acetic acid, acetone, anisole, 1-butanol, 2-butanol, butyl acetate, tert-butylmethyl ether, cumene, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, methylisobutyl ketone, 2-methyl-1-propanol, ethyl acetate, ethyl ether, ethyl formate, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, or any combination thereof.

### Claim 52 (depends on 51)

The method of claim 51, wherein the solvent system further comprises one or more organic solvents selected from chlorobenzene, cyclohexane, 1,2-dichloroethane, dichloromethane, 1,2-dimethoxyethane, formamide, hexane, 2-methoxyethanol, methylbutyl ketone, methylcyclohexane, nitromethane, tetralin, xylene, toluene, 1,1,2-trichloroethane, acetone, anisole, 1-butanol, 2-butanol, butyl acetate, tert-butylmethyl ether, cumene, ethanol, ethyl acetate, ethyl ether, ethyl formate, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, 2-methy-1-propanol, pentane, 1-propanol, 1-pentanol, 2-propanol, propyl acetate, tetrahydrofuran, or methyl tetrahydrofuran.

### Claim 53 (depends on 51)

The method of claim 51, wherein the solvent system further comprises one or more organic solvents selected from 2-ethoxyethanol, ethyleneglycol, methanol, 2-methoxyethanol, 1-butanol, 2-butanol, 3-methyl-1-butanol, 2-methyl-1-propanol, ethanol, 1-pentanol, 1-propanol, 2-propanol, methylbutyl ketone, acetone, methylethyl ketone, methylisobutyl ketone, butyl acetate, isobutyl acetate, isopropyl acetate, methyl acetate, ethyl acetate, propyl acetate, pyridine, toluene, xylene, or any combination thereof.

### Claim 54 (depends on 51)

The method of claim 51, wherein the solvent system further comprises one or more organic solvents selected from iso-propanol, acetone or any combination thereof.

### Claim 55

A method of preparing Form D of HCl salt of Compound (1), wherein Compound (1) is represented by the following structural formula:
comprising:
dehydrating Form A of HCl salt of Compound (1).½H2O.

### Claim 56

A method of preparing Form A of Compound (1), wherein Compound (1) is represented by the following structural formula:
comprising:
(a) stirring an amorphous Compound (1) or a solvate of Compound (1) in a solvent system comprising water and ethanol.

### Claim 57 (depends on 56)

The method of claim 56, wherein the stirring step is performed at a temperature in a range of 18° C. to 90° C.

### Claim 58 (depends on 56, 57)

The method of either of claim 56 or 57, wherein the solvent system comprises 5 wt % to 15 wt % of water by weight of the solvent system.

### Claim 59 (depends on 56, 57, 58)

The method of any one of claims 56-58, further comprising:
(b) stirring amorphous form of Compound (1) in nitromethane to form crystalline seed of Form A of Compound (1); and
(c) adding the crystalline seed of Form A of Compound (1) to the resulting mixture of the mixing step (a).

### Claim 60 (depends on 56, 57, 58, 59)

The method of any one of claims 56-59, wherein the stirring step (a) is performed at a refluxing temperature of the solvent system.

### Claim 61 (depends on 56, 57, 58)

The method of any of claims 56-58, further comprising:
(b) stirring the amorphous form of Compound (1) in nitromethane to form crystalline seed of Form A of Compound (1); and
(c) cooling the resulting mixture of the mixing step (a) to a temperature in a range of 18° C. to 60° C.; and
(d) adding the crystalline seed of Form A of Compound (1) to the resulting mixture step (c).

### Claim 62 (depends on 61)

The method of claim 61, further comprising adding water, prior to the addition of crystalline seed of Form A of Compound (1), to the resulting mixture that has gone through the refluxing step in an amount sufficient to impart the resulting solvent system with 15 wt % to 25 wt % of water after the addition of water.

### Claim 63 (depends on 61)

The method of claim 61, further comprising adding water to the mixture that includes crystalline seed of Form A of Compound (1) in an amount sufficient to impart the resulting solvent system with 35 wt % to 45 wt % of water after the addition of water.

### Claim 64 (depends on 61)

The method of claim 61, further comprising cooling the mixture that includes crystalline seed of Form A of Compound (1), after the addition of water, to a temperature of 0° C. to 10° C.

### Claim 65

A method of preparing Form A of tosylate salt of Compound (1), wherein Compound (1) is represented by the following structural formula:
comprising:
stirring a mixture of an amorphous Compound (1) or a solvate of Compound (1), p-toluenesulfonic acid, and a solvent system comprising acetonitrile.

### Claim 66

A 2-methyl tetrahyrdrofuran solvate of Compound (1), wherein Compound (1) is represented by the following structural formula:

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A dosage regimen comprising administering to a subject a polymorphic form of Compound (1) or a pharmaceutically acceptable salt thereof according to any one of claims 1-24 in a dosage amount of 100 mg to 1,600 mg, wherein the dosage amount is administered once, twice or three times per day.

### Claim 68 (depends on 67)

The dosage regimen of claim 67, wherein the dosage amount is 300 mg to 1,600 mg.

### Claim 69 (depends on 68)

The dosage regimen of claim 68, wherein the dosage amount is 600 mg to 1,200 mg.

### Claim 70 (depends on 69)

The dosage regimen of claim 69, wherein the dosage is administered once per day.

### Claim 71 (depends on 70)

The dosage regimen of claim 70, wherein the dosage amount is 600 mg or 800 mg.

### Claim 72 (depends on 68)

The dosage regimen of claim 68, wherein the dosage amount is 300 mg to 900 mg.

### Claim 73 (depends on 72)

The dosage regimen of claim 72, wherein the dosage is administered twice per day.

### Claim 74 (depends on 68)

The dosage regimen of claim 68, wherein the dosage amount is 400 mg or 600 mg.

### Claim 75 (depends on 67, 68, 69, 70, 71, 72, 73, 74)

The dosage regimen of any one of claims 67-74, wherein the polymorphic form of Compound (1) or a pharmaceutically acceptable salt thereof is administered for duration of treatment of 1 day to an entire flu season.

### Claim 76 (depends on 75)

The dosage regimen of claim 75, wherein the treatment duration is 3 days to 14 days.

### Claim 77 (depends on 76)

The dosage regimen of claim 76, wherein the treatment duration is 3 days, 4 days, or 5 days.

### Claim 78 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The dosage regimen of any one of claims 67-77, wherein a loading dosage amount of 600 mg to 1,600 mg is administered to the subject on day 1 and a dosage amount of 400 mg to 1,200 mg is administered to the subject for the rest of the treatment duration.

### Claim 79 (depends on 78)

The dosage regimen of claim 78, wherein a loading dosage amount of 900 mg to 1,600 mg is administered to the subject on day 1 and a dosage amount of 400 mg to 1,200 mg is administered to the subject for the rest of the treatment duration.

### Claim 80 (depends on 79)

The dosage regimen of claim 79, wherein a loading dosage amount of 900 mg or 1,200 mg is administered to the subject on day 1 and a dosage amount of 600 mg to 800 mg is administered to the subject for the rest of the treatment duration.

### Claim 81 (depends on 80)

The dosage regimen of claim 80, wherein a loading dosage amount of 900 mg is administered to the subject on day 1 and a dosage amount of 600 mg is administered once a day to the subject for the rest of the treatment duration.

### Claim 82 (depends on 80)

The dosage regimen of claim 80, wherein a loading dosage amount of 1,200 mg is administered to the subject on day 1 and a dosage amount of 600 mg is administered once a day to the subject for the rest of the treatment duration.
